Table 1

Results of interrupted time series analyses of the impacts of government price regulation and deregulation on Laspeyres price index, monthly average purchase volumes and spending for price-regulated, price-unregulated and all antineoplastic medications, as well as group differences, 2011–2016

Baseline levelBaseline trendPostregulation level changePostregulation trend changeChange at 12 months after regulationPostderegulation level changePostderegulation trend changeChange at
12 months after deregulation
Lp price index
 All medications0.993***−0.004*−0.057***0.001−0.032−0.0050.001−0.013
 Price-regulated medications0.988***−0.004*−0.082***0.001−0.058*−0.0030.0020.000
 Price-unregulated medications1.006***−0.003***0.0020.0010.029*−0.013*0.000−0.043*
 Difference between groups−0.015−0.002−0.081***0.001−0.0710.0050.0020.043*
Hospital purchase volume (thousand DDD)
 All medications38.086***0.9151.938−0.525−4.881−0.176−0.311−4.218
 Price-regulated medications58.502***1.4473.325−0.862−7.878−1.605−0.527−8.455
 Price-unregulated medications10.242***0.1930.004−0.068−0.8791.798−0.0171.573
 Difference between groups48.252***1.2583.273−0.798−7.097−3.370−0.510−10.003
Hospital purchase spending (million CNY)
 All medications11.129***0.168−0.092−0.083−0.8540.257−0.063−0.945
 Price-regulated medications12.628***0.239−0.778−0.178−2.821−0.323−0.013−0.912
 Price-unregulated medications9.085***0.0730.8320.0481.8061.052−0.132−0.992
 Difference between groups3.614***0.158*−1.570**−0.219**−4.508*−1.301*0.1170.122
  • Price-regulated medications: 30 antineoplastic products with price regulation in 2012 and deregulation in 2015. Price-unregulated medications: 22 antineoplastic products without price regulation or deregulation.

  • *p≤0.05; **p≤0.01; ***p≤0.001.

  • CNY, Chinese yuan (¥1=US$0.155 in 2011); DDD, defined daily dose; Lp, Laspeyres.